Passage Bio Statistics

Total Valuation

Passage Bio has a market cap or net worth of $15.08 million. The enterprise value is -$12.50 million.

Market Cap	15.08M
Enterprise Value	-12.50M

Important Dates

The next estimated earnings date is Tuesday, August 11, 2026, before market open.

Earnings Date	Aug 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Passage Bio has 3.21 million shares outstanding. The number of shares has increased by 0.55% in one year.

Current Share Class	3.21M
Shares Outstanding	3.21M
Shares Change (YoY)	+0.55%
Shares Change (QoQ)	+0.82%
Owned by Insiders (%)	0.50%
Owned by Institutions (%)	56.12%
Float	2.89M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.28
P/TBV Ratio	1.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.73, with a Debt / Equity ratio of 0.49.

Current Ratio	1.73
Quick Ratio	1.66
Debt / Equity	0.49
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -128.90% and return on invested capital (ROIC) is -53.47%.

Return on Equity (ROE)	-128.90%
Return on Assets (ROA)	-39.00%
Return on Invested Capital (ROIC)	-53.47%
Return on Capital Employed (ROCE)	-233.58%
Weighted Average Cost of Capital (WACC)	8.67%
Revenue Per Employee	n/a
Profits Per Employee	-$1.57M
Employee Count	24
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -27.91% in the last 52 weeks. The beta is 1.41, so Passage Bio's price volatility has been higher than the market average.

Beta (5Y)	1.41
52-Week Price Change	-27.91%
50-Day Moving Average	5.63
200-Day Moving Average	8.37
Relative Strength Index (RSI)	40.28
Average Volume (20 Days)	92,389

Short Selling Information

The latest short interest is 121,984, so 3.80% of the outstanding shares have been sold short.

Short Interest	121,984
Short Previous Month	162,626
Short % of Shares Out	3.80%
Short % of Float	4.23%
Short Ratio (days to cover)	1.87

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-38.21M
Pretax Income	-37.68M
Net Income	-37.68M
EBITDA	-37.55M
EBIT	-38.21M
Earnings Per Share (EPS)	-$11.84

Full Income Statement

Balance Sheet

The company has $33.34 million in cash and $5.76 million in debt, giving a net cash position of $27.58 million or $8.60 per share.

Cash & Cash Equivalents	33.34M
Total Debt	5.76M
Net Cash	27.58M
Net Cash Per Share	$8.60
Equity (Book Value)	11.75M
Book Value Per Share	3.66
Working Capital	14.64M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-30.65M
Capital Expenditures	n/a
Depreciation & Amortization	656,000
Net Borrowing	n/a
Free Cash Flow	-30.65M
FCF Per Share	-$9.55

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Passage Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.55%
Shareholder Yield	-0.55%
Earnings Yield	-249.90%
FCF Yield	-203.29%

Analyst Forecast

The average price target for Passage Bio is $12.67, which is 169.57% higher than the current price. The consensus rating is "Hold".

Price Target	$12.67
Price Target Difference	169.57%
Analyst Consensus	Hold
Analyst Count	4
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on July 14, 2025. It was a reverse split with a ratio of 1:20.

Last Split Date	Jul 14, 2025
Split Type	Reverse
Split Ratio	1:20

Scores

Altman Z-Score	n/a
Piotroski F-Score	1